Clinical trial
A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease
NCT04844606 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 26, 2021
- Completion date
- December 31, 2030
- Enrollment
- 150 (estimated)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease, inflammatory bowel diseases, ulcerative colitis, ulcerative colitis chronic